For example, genome editing of vascular endothelial growth factor A (Vegfa) and hypoxia-inducible factor 1-alpha (Hif1a) by CRISPR/CjCas9 in vivo is able to abolish angiogenesis in an age-related macular degeneration model, supporting the possibility of applying this approach for treating secondary glaucoma after cataract surgery. The gene discussed is VEGFA; the disease is age-related macular degeneration.